The strongest evidence favoring platinum-based/FOLFIRINOX strategies involves homologous recombination repair deficiency (HRD), especially alterations in germline breast cancer gene 1/2 (<i>BRCA1/2</i>) or partner and localizer of BRCA2 (<i>PALB2</i>), as well as broader genomic scar signatures. The gene discussed is BRCA2; the disease is breast carcinoma.